Company / Net Income
Apellis Pharmaceuticals, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$22.4M
FY2025
5-year range
-$746.4M / $22.4M
FY2021-FY2025
Trend
+111.3%
vs FY2024
Sector context
#54 of 216
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s net income of $22M is higher than 75% of companies in the Health Care sector (FY2025). Net Income has increased for 4 consecutive years, from -$746M in FY2021 to $22M in FY2025.
Based on SEC 10-K filings.
$22M in FY2025. Top quartile in the Health Care sector.
Improved from -$529M to $22M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 216This company $22.4M Sector average $454.3M
▼
-95.1% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s net income has grown for 4 consecutive years.
- In FY2025, net income increased 111.3% year-over-year.
- Ranks #54 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.4M | +111.3% |
| FY2024 | -$197.9M | +62.6% |
| FY2023 | -$528.6M | +18.9% |
| FY2022 | -$652.2M | +12.6% |
| FY2021 | -$746.4M | -116.4% |
| FY2020 | -$344.9M | -13.2% |
| FY2019 | -$304.7M | -139.0% |
| FY2018 | -$127.5M | -150.0% |
| FY2017 | -$51.0M | -88.0% |
| FY2016 | -$27.1M | +41.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026